Multivariable model demonstrating the relationship of tumor mutation status with >5% loss of skeletal muscle and >5% loss of weight
| Time point, mutation . | >5% weight loss . | >5% skeletal muscle loss . | ||
|---|---|---|---|---|
| OR (95% CI) . | p value . | OR (95% CI) . | p value . | |
| 3 mo | ||||
| WT | Ref | Ref | ||
| BRAF | 1.543 (0.521 – 4.568) | .4332 | 1.786 (0.727 – 4.387) | .2057 |
| RAS | 0.840 (0.366 – 1.926) | .6801 | 0.972 (0.483 – 1.975) | .9355 |
| 6 mo | ||||
| WT | Ref | Ref | ||
| BRAF | 2.379 (0.778 – 7.274) | .1284 | 3.372 (1.273 – 8.933) | .0144 |
| RAS | 1.188 (0.493 – 2.862) | .7016 | 1.144 (0.538 – 2.435) | .7261 |
| 12 mo | ||||
| WT | Ref | Ref | ||
| BRAF | 4.426 (0.982 – 19.957) | .0529 | 5.533 (1.604 – 19.091) | .0068 |
| RAS | 2.217 (0.717 – 6.853) | .1666 | 1.577 (0.667 – 3.727) | .2991 |
| Time point, mutation . | >5% weight loss . | >5% skeletal muscle loss . | ||
|---|---|---|---|---|
| OR (95% CI) . | p value . | OR (95% CI) . | p value . | |
| 3 mo | ||||
| WT | Ref | Ref | ||
| BRAF | 1.543 (0.521 – 4.568) | .4332 | 1.786 (0.727 – 4.387) | .2057 |
| RAS | 0.840 (0.366 – 1.926) | .6801 | 0.972 (0.483 – 1.975) | .9355 |
| 6 mo | ||||
| WT | Ref | Ref | ||
| BRAF | 2.379 (0.778 – 7.274) | .1284 | 3.372 (1.273 – 8.933) | .0144 |
| RAS | 1.188 (0.493 – 2.862) | .7016 | 1.144 (0.538 – 2.435) | .7261 |
| 12 mo | ||||
| WT | Ref | Ref | ||
| BRAF | 4.426 (0.982 – 19.957) | .0529 | 5.533 (1.604 – 19.091) | .0068 |
| RAS | 2.217 (0.717 – 6.853) | .1666 | 1.577 (0.667 – 3.727) | .2991 |
Body composition change was evaluated on computed tomography scans obtained 3, 6, and 12 months following the date of metastatic diagnosis. Estimates are adjusted for potential confounders, including age, sex, and baseline skeletal muscle or baseline weight. For the values of all covariables see supplemental online Table 4.
Abbreviations: CI, confidence interval; OR, odds ratio; Ref, reference; WT, wild type.
Multivariable model demonstrating the relationship of tumor mutation status with >5% loss of skeletal muscle and >5% loss of weight
| Time point, mutation . | >5% weight loss . | >5% skeletal muscle loss . | ||
|---|---|---|---|---|
| OR (95% CI) . | p value . | OR (95% CI) . | p value . | |
| 3 mo | ||||
| WT | Ref | Ref | ||
| BRAF | 1.543 (0.521 – 4.568) | .4332 | 1.786 (0.727 – 4.387) | .2057 |
| RAS | 0.840 (0.366 – 1.926) | .6801 | 0.972 (0.483 – 1.975) | .9355 |
| 6 mo | ||||
| WT | Ref | Ref | ||
| BRAF | 2.379 (0.778 – 7.274) | .1284 | 3.372 (1.273 – 8.933) | .0144 |
| RAS | 1.188 (0.493 – 2.862) | .7016 | 1.144 (0.538 – 2.435) | .7261 |
| 12 mo | ||||
| WT | Ref | Ref | ||
| BRAF | 4.426 (0.982 – 19.957) | .0529 | 5.533 (1.604 – 19.091) | .0068 |
| RAS | 2.217 (0.717 – 6.853) | .1666 | 1.577 (0.667 – 3.727) | .2991 |
| Time point, mutation . | >5% weight loss . | >5% skeletal muscle loss . | ||
|---|---|---|---|---|
| OR (95% CI) . | p value . | OR (95% CI) . | p value . | |
| 3 mo | ||||
| WT | Ref | Ref | ||
| BRAF | 1.543 (0.521 – 4.568) | .4332 | 1.786 (0.727 – 4.387) | .2057 |
| RAS | 0.840 (0.366 – 1.926) | .6801 | 0.972 (0.483 – 1.975) | .9355 |
| 6 mo | ||||
| WT | Ref | Ref | ||
| BRAF | 2.379 (0.778 – 7.274) | .1284 | 3.372 (1.273 – 8.933) | .0144 |
| RAS | 1.188 (0.493 – 2.862) | .7016 | 1.144 (0.538 – 2.435) | .7261 |
| 12 mo | ||||
| WT | Ref | Ref | ||
| BRAF | 4.426 (0.982 – 19.957) | .0529 | 5.533 (1.604 – 19.091) | .0068 |
| RAS | 2.217 (0.717 – 6.853) | .1666 | 1.577 (0.667 – 3.727) | .2991 |
Body composition change was evaluated on computed tomography scans obtained 3, 6, and 12 months following the date of metastatic diagnosis. Estimates are adjusted for potential confounders, including age, sex, and baseline skeletal muscle or baseline weight. For the values of all covariables see supplemental online Table 4.
Abbreviations: CI, confidence interval; OR, odds ratio; Ref, reference; WT, wild type.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
